|
|
CD226 |
|
Vaxjo ID |
222 |
|
Vaccine Adjuvant Name |
CD226 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
Ag85A (Antigen-85A) is one of the major proteins secreted by *Mycobacterium tuberculosis*. CD226 is a member of the immunoglobulin superfamily, expressed in NK cells, T cells, monocytes, and platelets. |
|
Stage of Development |
Research |
|
Components |
CD226, a member of the immunoglobulin superfamily, is expressed in the majority of NK cells, T cells, monocytes, and platelets, and can be served as a co-stimulator that contributes to multiple innate and adaptive responses. |
|
Structure |
CD226 is a member of the immunoglobulin superfamily; Ag85A is a secreted protein. |
|
Preparation |
The study involved oral vaccination with pcDNA3.1-Ag85A-CD226 DNA. |
|
Dosage |
The study involved oral vaccination in mice, but specific dosage quantities are not provided in the abstract. |
|
Function |
CD226 was an effective genetic adjuvant that improved the immune efficacy induced by Ag85A and enhanced the activity of cytotoxic T lymphocytes (CTL) and NK cells in mice. |
| Related Vaccine(s) |
|
| References |
Li et al., 2015: Li Y, Yang F, Zhu J, Sang L, Han X, Wang D, Shan F, Li S, Sun X, Lu C. CD226 as a genetic adjuvant to enhance immune efficacy induced by Ag85A DNA vaccination. International immunopharmacology. 2015; 25(1); 10-18. [PubMed: 25582686].
|
|
